TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Buy" from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $11.79.

Several research firms have issued reports on TLSI. Roth Mkm initiated coverage on TriSalus Life Sciences in a report on Monday, November 11th. They set a "buy" rating and a $11.00 price objective on the stock. Canaccord Genuity Group cut their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Monday, November 11th. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an "overweight" rating and a $10.00 target price on the stock. Finally, Oppenheimer began coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an "outperform" rating and a $10.00 target price for the company.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius bought 62,972 shares of the firm's stock in a transaction on Tuesday, December 17th. The stock was bought at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now directly owns 6,230,748 shares of the company's stock, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have purchased 70,012 shares of company stock valued at $281,235. 32.80% of the stock is owned by insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the second quarter valued at about $1,184,000. Duquesne Family Office LLC raised its stake in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after acquiring an additional 110,966 shares in the last quarter. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $184,000. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $66,000. Finally, Geode Capital Management LLC boosted its position in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after purchasing an additional 62,542 shares during the period. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Trading Down 7.2 %

Shares of TriSalus Life Sciences stock traded down $0.37 on Thursday, reaching $4.78. 27,585 shares of the company were exchanged, compared to its average volume of 22,697. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The firm has a market capitalization of $145.76 million, a price-to-earnings ratio of -1.92 and a beta of 0.51. The stock has a fifty day moving average price of $4.34 and a 200-day moving average price of $4.81.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.